Addendum
Lenvatinib (endometrial carcinoma) - Addendum to Commission A21-162
Report documents
-
Addendum
Lenvatinib (endometrial carcinoma) - Addendum to Commission A21-162
Dossier assessment
Indication:
Adults with advanced or recurrent endometrial cancer whose disease has progressed during or after prior platinum-based chemotherapy at any stage of the disease, when surgery or radiation to cure the cancer is not an option for them
Result of dossier assessment:
Unchanged after addendum:
- Patients for whom doxorubicin or paclitaxel is the suitable therapy according to physician’s choice: indication of considerable added benefit
- Patients for whom a treatment option other than doxorubicin or paclitaxel is the suitable therapy according to physician’s choice: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2022-07-07 A G-BA decision was published.
Project details
- Project no.
- A22-57
- Commission
- Commission awarded on 25.05.2022 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Lenvatinib (endometrial carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed